ReNeuron Group plc
http://www.reneuron.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ReNeuron Group plc
SK Biopharm Moves Into Radiopharma Via $572m Full-Life Deal
After acquiring a majority stake in ProteoVant last year, South Korea's SK Biopharm is continuing to hunt for new modalities and is now moving into the hot radiotherapeutics area through a deal with Full-Life Technologies.
SK Bioscience Snaps Up IDT Biologika To Accelerate Growth
SK Bioscience’s acquisition of top 10 CDMO marks first major acquisition as part of its growth acceleration strategy and the biggest such investment so far by a Korean vaccines firm. Execs say deal is aligned with SK Group’s wider moves to 'rebalance' its businesses.
Korea’s Clinical Trial Approvals Up 10%, But Still Below Pandemic Peak
South Korea’s clinical trial approvals rebounded in 2023, but remained lower than the peak levels in 2020-21 amid then robust R&D activity related to COVID-19. Last year's tally showed a mix of single-country and multinational trials and reflected the ongoing dominance of oncology in industry pipelines.
Will Actinium Be Big Pharma’s Next Radiopharmaceuticals Acquisition?
With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice